Vancouver, Canada

Aquinox Pharmaceuticals Inc.

Calculating rank
USPTO Granted Patents = 5

% Expired Patents = 40.0


Forward Citations = 36

Loading Chart...
Loading Chart...

15 inventors (with patents filed for the assignee):

goldMedal Jeffery R Raymond (4 out of 14 patents)

silverMedal Yuehua He (4 out of 5 patents)

bronzeMedal Kang Han (4 out of 4 patents)

4.  Yuanlin Zhou (4 out of 11 patents)

5.  Bradley Noren (4 out of 4 patents)

6.  James Gee Ken Yee (4 out of 10 patents)

7.  Curtis Harwig (1 out of 32 patents)

8.  Vladimir Khlebnikov (1 out of 6 patents)

9.  Lloyd F Mackenzie (1 out of 12 patents)

10.  Rudong Shan (1 out of 6 patents)

11.  Jeremy D Pettigrew (1 out of 18 patents)

12.  Tom MacRury (1 out of 1 patent)

13.  Noor Aini Bhatti (1 out of 1 patent)

14.  Sam Place (1 out of 1 patent)

15.  Paul Bird (1 out of 3 patents)


5 patents:

Company Overview
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that focuses on developing and commercializing novel therapies for the treatment of inflammation and cancer. Their lead product candidate, Rosiptor, is being developed for the treatment of interstitial cystitis/bladder pain syndrome and bladder cancer. Aquinox is dedicated to improving the lives of patients through innovative treatments and targeted therapies.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Nov 10 2026

5 Patents

#182 in Vancouver

#2,859 in Canada

Vancouver, CA
Vancouver, Canada
Forward Citations = 36

15 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Aquinox Pharmaceuticals Inc.. Retrieved from https://idiyas.com/company/aquinox-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…